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ABSTRACT We aimed to investigate differences in the electroencephalography (EEG) signal characteristics
recorded with a type II polysomnography (PSG) setup including the American Academy of Sleep Medicine
recommended EEG montage and Self Applied Somnography (SAS) setup. The PSG and SAS monitoring
were simultaneously performed in a pediatric cohort (n = 111) with Nox A1 equipment (Nox Medical,
Reykjavik, Iceland). The PSG channels F4-M1 and F3-M2 were compared to the SAS channels AF4-
E3E4 and AF3-E3E4. The analyses were conducted separately in each sleep stage. The amplitude levels
were compared by investigating envelope curves of each epoch and the frequency content by investigating
the power spectrums obtained with Welch’s method. The EEG spectral morphology was similar between
SAS and PSG. However, the SAS had consistently lower median amplitudes in all sleep stages compared
to the PSG. In Stage N3 (slow-wave sleep), the lower and upper envelope curves had 42.4–47.4% lower
median absolute amplitudes. Similarly, the SAS channels had consistently less power in the whole analysed
frequency range of 0.3–35 Hz. In conclusion, the results illustrate that the SAS signals have similar EEG
spectral morphology but consistently lower amplitudes and less power across the whole EEG frequency
range compared to PSG signals. To achieve scoring corresponding to PSG, either the raw SAS signals
should be digitally preprocessed or the amplitude threshold for identifying N3 should be lowered from
75 µV to e.g. 45 µV when using SAS instead of PSG. Further clinical validation studies are required to
demonstrate scoring reliability using modified scoring rules.
INDEX TERMS Electroencephalography, pediatric sleep disorders, polysomnography, self-applied
somnography, sleep staging, spectral analysis.
The associate editor coordinating the review of this manuscript and
approving it for publication was Gang Wang .
I. INTRODUCTION
Sleep disorders form a growing global health problem and
cause significant economical costs [1]. One of the most
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common sleep disorders, obstructive sleep apnea (OSA),
is globally affecting over 900 million adults [2] and up
to 6% of children [3]. The gold standard in diagnosing
sleep disorders, both in adult and pediatric populations,
is polysomnography (PSG) conducted at a sleep laboratory.
PSG records electroencephalography (EEG), electrooculog-
raphy (EOG), electromyography (EMG), and cardiorespira-
tory signals among others. From these, the EEG, EOG, and
chin EMG signals are the basis of sleep staging used to
provide information on the sleep architecture and the total
sleep time [4].
Sleep staging can be considered the cornerstone of sleep
medicine. In OSA diagnostics, sleep staging provides invalu-
able information on the sleep architecture and sleep quality
and helps differentiate between various sleep disorders.
Accurate sleep staging is especially crucial as the most
often used diagnostic parameters (e.g. apnea-hypopnea index,
periodic limb movement index, and arousal index) rely on
the determined total sleep time. In children, the importance
of accurate determination of sleep stages is even greater
due to lower parameter thresholds and more strict diagnostic
criteria [5], [6]. The main limiting issue with PSG is that it
suffers from high costs and limited availability. Type I PSG
requires the patient to sleep in an unfamiliar environment
which can negatively impact sleep quality [7] and continuous
monitoring by trained staff is necessary [8]. Type II PSGs,
where the electrodes are placed at a sleep laboratory and the
patient sleeps at home, still require approximately a 1-hour
setup by sleep laboratory staff [8]. This can be impractical
for the patient and the electrodes are prone to be detached [9].
To diagnose OSA in adults, simpler type III polygraphy can
be used [4]; however, these cannot identify sleep stages due
to the absence of the EEG, EOG, and chin EMG recording
montage. Furthermore, type III polygraphy is not accepted
internationally for diagnosis of pediatric OSA [4], [10].
To overcome these issues, easily applicable electrode sets
and wearable EEG devices have been developed [11]–[13].
For example, sleep staging based on a screen-printed ambula-
tory electrode set [14] has reached a good correspondence to
type I diagnostic PSG [15], [16]. Various consumer devices,
such aswristbands, smartwatches, and rings for sleep tracking
also exist. However, these often suffer from low concordance
compared to PSG especially during disordered sleep [17].
Furthermore, there have also been promising approaches
attempting sleep staging with machine learning using only
a single channel EEG, electrocardiogram, or photoplethys-
mogram signals to enable a simpler measurement setup
compared to PSG [18], [19]. However, sleep staging from
surrogate signals to EEG is still not as accurate as EEG-
based analysis [19], [20], and cannot yet be adapted to the
current clinical protocol. Therefore, EEG is required when
the accuracy of sleep staging is crucial.
One potential solution is the recently introduced Self
Applied Somnography (SAS) setup (Nox Medical, Reyk-
javik, Iceland), a simplified EEG montage, developed for
self-applicable use in a non-hospital environment (Figure 1).
FIGURE 1. The EEG setup used in the Self Applied Somnography (SAS).
Figure courtesy of Nox Medical, Reykjavik, Iceland.
Compared to traditional EEG montage, it introduces fixed-
position frontal montage including ten electrodes and EOG-
based referencing without recording the mastoid channels.
SAS does not include chin EMG but introduces an EMG
derived from the eye electrodes (not yet clinically validated).
As the sleep stages are determined by visual inspection of
the EEG signals performed by trained sleep technologists
or physicians, measurement setups should be comparable to
each other to reach a sufficient level of similarity. This is espe-
cially crucial for identifying deep sleep with the requirement
of fixed peak-to-peak levels of the delta oscillations. The
possibility to use the predefined scoring rules of theAmerican
Academy of Sleep Medicine (AASM) [4] should be carefully
addressed.
In this study, we aim to investigate the differences in
the EEG signal characteristics obtained via simultaneous
type II PSG and SAS recording in a pediatric cohort.
We particularly focus on the differences in amplitude levels
and frequency-domain characteristics within different sleep
stages when PSG-EEG and SAS-EEG signals are recorded
simultaneously.
II. METHODS
A. DATA COLLECTION, DEMOGRAPHICS, AND SLEEP
SCORING
The participants in this study were 11–14-year-old Icelandic
children from the Icelandic EuroPrevall/iFAAM (Integrated
Approaches to FoodAllergen andAllergy RiskManagement)
birth cohort study [21]–[23]. The Europrevall study in
Iceland [24] included a questionnaire two years before the
present study to the parents on the snoring and witnessing of
apneas in their children. All children who were reported to
snore at least three times a week or had witnessed apneas
at least once a week (n = 109) in the questionnaire
were invited to participate in the present study. Out of the
invited, 55% agreed to participate (n = 60). Moreover,
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FIGURE 2. The flowchart of the study participant inclusion.
PSG = polysomnography, SAS = Self Applied Somnography,
EEG = electroencephalography.
children without reported snoring or apneas were invited to
participate as age- and gender-matched controls (n = 58).
In the present study, all participants were investigated as a
single group leading to a study population of 118 participants.
However, a total of four SAS or PSG recordings had<4 hours
of successful recording of EEG, two studies failed, and
one participant declined the full usage of data; thus, these
participants were excluded from the present study. The final
study population included 111 participants (Figure 2). The
demographic information of the participants is summarized
in Table 1. This study was approved by the Ethical
Committee of Landspitali - the National University Hospital
of Iceland and the National Bioethics Committee of Iceland
(VSN 18-206) and an informed written consent was obtained
from a parent and/or legal guardian of all participants.
The participants went through a simultaneous type II
PSG and a SAS recording conducted with two separate
Nox A1 devices (Nox Medical, Reykjavik Iceland). The
equipment was setup up by experienced sleep technologists
at the Landspitali University Hospital, Children‘s Hospital,
Reykjavik, Iceland and the measurements were conducted
during a single night at the participants’ home. The PSG
included a recording of EEG (F4-M1, C4-M1, O2-M1 signals
with the F3-M2, C3-M2, and O1-M2 signals as backup),
EOG (E1-M2, and E2-M2), and chin EMG that were used
for identifying the sleep stages. The SAS setup included a
TABLE 1. The demographic and polysomnographic information of the
study population.
FIGURE 3. Illustration of the electroencephalography (EEG) signal
envelopes. Minimum and maximum amplitude levels were determined as
a mean of the upper and lower envelopes, respectively. Envelopes were
computed using 50-point cubic spline interpolation.
recording of frontal EEG (AF4, AF3, AF8, and AF7) and
EOG (E1, E2, E3, and E4) with placements approximately
1 cm above and below each eye (Figure 1). Patches with
two electrodes were used to provide redundancy in case of
electrode failure while also allowing the symmetric form
and a mechanically stable structure. The EEG channels were
referenced to the averaged EOG channel measured below
the eyes, i.e. to channel E3E4. This referencing is used to
minimize the eye movement artefacts in the EEG.
B. DATA ANALYSIS
The recordings were annotated by expert sleep technologists
in accordance with the AASM manual, version 2.5 [4] using
Noxturnal version 5.1 software (Nox Medical, Reykjavik,
Iceland). The sleep stages were identified from the PSG
recordings. Only the epochs which were identified as
Stages W (wake), N1, N2, N3, or R (rapid eye movement
sleep) were included in the analysis. The EEG signals
from both montages, AF4-E3E4 and AF3-E3E4 from SAS
and F4-M1 and F3-M2 from PSG, were exported from
Noxturnal software with a sampling frequency of 200 Hz.
No preprocessing of the signals was conducted. All epochs
were first extracted in a subject-by-subject manner, and
then pooled based on the sleep stage. The total number of
analysed epochs was 115312, out of which 3471 were Stage
N1, 28139 Stage N2, 53204 Stage N3, 22290 Stage R, and
8208 Stage W.
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TABLE 2. Comparison of median lower and upper envelope amplitude levels within different sleep stages from PSG (F4-M1 and F3-M2) vs. SAS
(AF4-E3E4 and AF3-E3E4).
For amplitude level analyses, upper and lower envelope
curves of each epoch were computed using a 50-point
cubic spline interpolation between detected minimums and
maximums (Figure 3). Envelopes were analysed to identify
possible voltage drift and amplitude levels in all sleep stages,
as only Stage N3 has a defined peak-to-peak threshold to
the AASM sleep scoring manual [4]. Subsequently, the mean
values of the lower and upper envelopes were computed. This
procedure was performed similarly for all analysed signals.
After computing themeans, themedian and the distribution of
means of upper and lower envelopes were determined. These
were compared between PSG and SAS and the statistical
significance was determined by Wilcoxon’s rank-sum test.
Additionally, the upper and lower envelope amplitudes were
investigated via box plots to better visualize the differences
in the morphology of the distributions. No variables were
assumed to be normally distributed. As the sample sizes (i.e.
number of epochs) were large, the threshold for statistical
significance was chosen to be 0.001. All the analyses were
conducted using Matlab (version 2018b; The MathWorks,
Natick, MA, USA).
In addition to amplitude analyses, the frequency content
of each epoch was determined. The power spectrums were
computed using Welch’s method. The analysed frequency
range was 0.3–35 Hz [4], with 50% overlapping of the
subsequent partitions, Hamming window, and window size
of 1125 points. Before computing the spectrums, each epoch
was normalized by subtracting the mean and dividing the
values with the standard deviation of the corresponding
signal. After the computation of spectrums, the median
power spectrum of each signal within each sleep stage was
determined.
Moreover, based on preliminary results, the frequency
band 10 – 15 Hz was further analyzed to investigate a shift in
alpha-band peak power between PSG and SAS. Within this
frequency range, the peak power frequency was determined
for all Stage N2 and Stage N3 epochs from all recordings.
From these, the empirical cumulative distributions were
determined and the statistical differences between PSG and
SAS was further evaluated using Kolmogorov-Smirnov test.
III. RESULTS
A. AMPLITUDE COMPARISON
The SAS channels AF4-E3E4 and AF3-E3E4 showed
consistently lower median amplitudes based on envelope-
means in all sleep stages compared to corresponding PSG
channels F4-M1 and F3-M2, respectively (Table 2). The only
exception was the median lower envelope of SAS in Stage
N1 for AF4-E3E4. In addition, the upper and lower envelopes
of SAS channels had a broader or similar interquartile range
compared to interquartile ranges of PSG envelopes in Stages
N2, N3, and R (Figures 4 and 5). In Stages W and N1, the
interquartile ranges were broader in PSG channels, except in
F3-M2 in Stage N1 (Figures 4 and 5).
B. SPECTRAL ANALYSIS
In frequency-domain comparison, the overall spectral mor-
phology was similar between PSG and SAS. However, a sub-
stantial difference in absolute and relative power content was
observed between the median power spectrums (Figure 6).
F4-M1 and F3-M2 channels had consistently higher powers
in the whole analysed frequency range (Figure 6). In Stages
N2 and N3, a small but systematic and statistically significant
(p < 0.001) shift in alpha-band peak power towards lower
frequencies was observed in both SAS channels compared
to PSG channels (Figure 7). In Stage N2, the median alpha-
band peak power frequency was 11.84 Hz and 11.92 Hz for
F3-M2 and F4-M1, respectively. In the SAS channels,
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FIGURE 4. Comparison of minimum and maximum amplitude levels in different sleep stages between F4-M1 (PSG) and AF4-E3E4 (SAS).
The red line in the box indicates the median value, edges of the box represent the interquartile range and whiskers indicate 99.3%
coverage of the data. Extreme outliers are not presented. Abbreviations: PSG = polysomnography, SAS = Self Applied Somnography, W =
wake, R = rapid eye movement.
the median frequencies were 11.43 Hz and 11.41 Hz
for AF4-E3E4 and AF3-E3E4, respectively. In Stage N3,
the frequencies were 11.56 Hz for F4-M1, 11.54 Hz
for F3-M2, 11.28 Hz for AF4-E3E4, and 11.27 Hz for
AF3-E3E4. Only negligible differences between right and
left channels were observed in amplitude or frequency-
domain comparisons between AF4-E3E4 and AF3-E3E4 or
F4-M1 and F3-M2, except during StageW (Table 2, Figure 6,
and Figure 7).
IV. DISCUSSION
In the present study, we investigated the differences in EEG
signal characteristics between type II PSG and a Self Applied
Somnography (SAS) setup. We found consistently lower
EEG signal amplitudes when EEG was measured using the
SAS setup. The amplitudes of SAS-EEG signals were over
40% lower in median within all sleep stages. Moreover,
the frontal EEG channels of PSG showed substantially higher
power in the whole clinical frequency range compared to the
SAS setup. These results imply that preprocessing of the raw
EEG signals, relying on the SAS setup, is required prior to
manual sleep staging.
The amplitudes of the SAS-EEG signals were consistently
lower than those of the PSG-EEG. The most likely explana-
tion is the different referencing of the signals. The locations of
the electrodes used for the EOG-based referencing (channel
E3E4) differ from the traditional mastoid electrodes (M1 or
M2). It results in similar EEG waveforms but different
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FIGURE 5. Comparison of minimum and maximum amplitude levels in different sleep stages between F3-M2 (PSG) and AF3-E3E4
(SAS). The red line in the box indicates the median value, edges of the box represent the interquartile range and whiskers indicate
99.3% coverage of the data. Extreme outliers are not presented. Abbreviations: PSG = polysomnography, SAS = Self Applied
Somnography, W = wake, R = rapid eye movement.
absolute characteristics. Moreover, the electrodes AF4 and
AF3 from the fixed montage are also located close to
the actual F4 and F3 placements but not in the same
exact locations, which may have a minor additional effect.
Furthermore, the SAS relies on self-adhesive electrodes
whereas the EEG electrodes used for PSG have an additional
conducting paste. This can lead to differing skin electrode
impedances and may have a minor effect on the obtained
results.
The observed differences in the raw EEG signal charac-
teristics may pose a challenge in detecting Stage N3 due to
differences in delta-band power. Stage N3 is characterized
by delta oscillations located in 0.5–2 Hz frequencies [4].
These oscillations have to reach a fixed 75 µV peak-to-peak
amplitude to allow the scorer to differentiate the Stage
N3 from Stage N2 [4]. Stage N2 is characterized by
theta-frequencies, sleep spindles, and K-complexes located
around 9–16 Hz frequency band [4], [25], but may also
have simultaneous delta-oscillation with lower peak-to-
peak amplitudes compared to Stage N3 [26]. The present
results show that the SAS setup produces significantly lower
amplitudes within Stage N3 compared to type II PSG. Aside
from differences in the spectral power, the only noticeable
difference between the frequency content of SAS and PSG
was a small but systematic shift in alpha-band peak power
frequency in Stages N2 and N3 (Figure 6 and Figure 7). The
EOG-referencing and the placement of the SAS electrodes
could contribute to the shift in alpha-peak power. However,
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FIGURE 6. Logarithmic median power spectral density (PSD) estimates for channels AF4-E3E4 (SAS), AF3-E3E4
(SAS), F4-M1 (PSG), and F3-M2 (PSG) in all sleep stages and the relative difference in spectral power content
between SAS and PSG. Abbreviations: PSG = polysomnography, SAS = Self Applied Somnography, W = wake, R =
rapid eye movement.
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FIGURE 7. The empirical cumulative distributions for alpha-band peak power frequencies between 10 – 15 Hz for channels AF4-E3E4 (SAS),
AF3-E3E4 (SAS), F4-M1 (PSG), and F3-M2 (PSG) in sleep stages N2 and N3. Abbreviations: PSG = polysomnography, SAS = Self Applied
Somnography.
the alpha shift was small, ranging from 0.27 to 0.49 Hz,
and thus should not affect the visual scoring of Stage N2.
More studies are warranted to verify the scoring concordance
between PSG and SAS.
It is noteworthy, that the observed differences in the
spectral and amplitude content between PSG and SAS are
possible to overcome. As seen in the median spectrums,
the spectral morphology is highly similar between SAS and
PSG. Thus, even though amplitude levels differ, the frequency
characteristics produced by the SAS setup are comparable
to PSG. Besides the decreased delta-power in SAS channels,
the only observable difference was the lower alpha-band peak
power frequency in Stages N2 andN3. However, the observed
shift was minor, and should not affect the identification of
sleep spindles and other alpha-band characteristics of EEG.
This indicates that for sleep staging, similar scoring as with
PSG may be achieved by digitally preprocessing (e.g. ampli-
fying certain frequency bands) the raw SAS EEG signals or
lowering the amplitude threshold required for scoring Stage
N3 when analyzing EEG measured with SAS. However,
the studied EEG signal characteristics do not provide
information on individual epoch-by-epoch differences but
rather on the averages. Therefore, further studies are required
to validate how well a manual scorer succeeds in identify-
ing different sleep stages from SAS recordings compared
to PSG.
The present study of EEG signal characteristics of SAS
was conducted in a pediatric population aged 11–14 years;
thus, the results cannot be generalized to other populations.
Measuring the EEG with a self-applicable electrode set has
different practical issues in children compared to adults. For
instance, the electrode placement with a fixed electrode set
differs due to the differing facial size. Therefore, further
studies are required to confirm the technical quality of SAS
recording in an adult population as well as in a pediatric
population with a broader age range. In addition, the dataset
comprised two distinct groups: snorers and the control
group. No comparison between these groups was conducted.
However, as this was an epoch-by-epoch technical signal
quality comparison, this should not affect the obtained results.
A further limitation of the present study is the slight
positive bias caused by the electrode placement protocol. The
SAS was placed together with the normal EEG setup by
the sleep technicians. Thus, the study does not provide
information on the self-application success rate. However,
setup by sleep technicians was necessary to obtain a reliable
comparison of the technical quality of the signals in a best-
case scenario without unnecessary confounding factors. The
reliability and feasibility of the use of the SAS on children in
the home setting with parent setup will be a future research
topic. Moreover, this study did not compare artefact tendency
between EEG recordings from SAS and PSG. One of themost
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common artefact in overnight EEG recordings is the sweat
artefact. Sweat artefacts are visible in the delta-range and they
mimic the slow-wave oscillations due to different impedance
characteristics of the skin-electrode interface when sweat is
present [27]–[29]. They are a common problem especially
in sleep apnea populations as the patients often suffer from
excessive nocturnal sweating [30], [31]. Sweat artefacts are
also related to material selections of the electrodes [30], [31].
As the power in the SAS delta-band did not reach the
powers of PSG in any sleep stage, it can be speculated
that SAS is as susceptible to sweat artefacts as PSG-EEG.
However, sweat artefact analysis was outside the scope of the
current paper. Therefore, more detailed studies are warranted
to investigate how susceptible the SAS setup is to sweat
artefacts and whether the different referencing of the EEG
signals affects artefact appearance. Finally, the PSG-EEG
and SAS-EEG recordings were conducted with two separate
Nox A1 amplifiers which can potentially lead to small
synchronization issues. However, these limitations were
acknowledged in the study design phase and themethodology
was chosen correspondingly such that small differences in
synchronization pose no significant issues.
V. CONCLUSION
The EEG signals recorded with the SAS setup had sim-
ilar spectral morphology but consistently lower ampli-
tudes and less power across the analysed frequency range
of 0.3–35 Hz. Therefore, the raw EEG signals should
be digitally preprocessed before scoring or the amplitude
threshold for identifying Stage N3 from the SAS recording
should be lowered. Based on the present data, we propose a
cutoff value of 45µV for peak-to-peak slow-wave oscillation
to be used with SAS in pediatric studies when identifying
Stage N3 if no additional preprocessing is conducted.
However, further studies are required to verify the accuracy
of the proposed threshold in different study populations.
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